Provided by Tiger Trade Technology Pte. Ltd.

Pharvaris N.V.

31.19
+0.18000.58%
Post-market: 31.190.00000.00%19:50 EDT
Volume:591.39K
Turnover:18.44M
Market Cap:2.18B
PE:-10.42
High:31.55
Open:31.21
Low:30.69
Close:31.01
52wk High:43.25
52wk Low:20.65
Shares:69.86M
Float Shares:44.23M
Volume Ratio:0.89
T/O Rate:1.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.9943
EPS(LYR):-3.4871
ROE:-70.46%
ROA:-42.32%
PB:6.43
PE(LYR):-8.94

Loading ...

Pharvaris N.v. : RBC Raises Target Price to $62 from $52

THOMSON REUTERS
·
Sep 09

Pharvaris: Kbc Securities Raises Target Price to $49 from $39; Rating Buy

THOMSON REUTERS
·
Sep 09

Pharvaris price target raised to $75 from $50 at Oppenheimer

TIPRANKS
·
Sep 09

U.S. Stocks on the MOVE-Best Buy, Peloton, Apple

Reuters
·
Sep 09

Top Midday Gainers

MT Newswires Live
·
Sep 09

Pharvaris Shares Rise on Positive Results for Hereditary Angioedema Trial

Dow Jones
·
Sep 08

Wedbush Adjusts Pharvaris Price Target to $50 From $42, Maintains Outperform Rating

MT Newswires Live
·
Sep 08

Pharvaris rises 16.7%

TIPRANKS
·
Sep 08

U.S. Stocks on the MOVE-Sigma Lithium, Shake Shack, Novartis

Reuters
·
Sep 08

Shares of Pharvaris up 14% After Co's Genetic Disorder Drug Meets Main Goal in Late-Stage Trial

THOMSON REUTERS
·
Sep 08

Pharvaris Price Target Maintained with a $42.00/Share by Wedbush

Dow Jones
·
Sep 08

Pharvaris Unveils CHAPTER-3 Phase 3 Topline Data and HAE Pipeline Milestones

TIPRANKS
·
Sep 08

Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Tuesday Amid Rising Oil Prices

MT Newswires Live
·
Sep 08

Pharvaris Gains After Genetic Disorder Drug Meets Late-Stage Trial Goal

Reuters
·
Sep 08

Shares of Pharvaris up 26.5% Premarket After Co's Genetic Disorder Drug Meets Main Goal in Late-Stage Trial

THOMSON REUTERS
·
Sep 08

Pharvaris Posts Strong Phase 3 HAE Prophylaxis Data for Oral Deucrictibant XR

TIPRANKS
·
Sep 08

Pharvaris announces positive topline data from deucrictibant in HAE attacks

TIPRANKS
·
Sep 08

Pharvaris Says Phase 3 Chapter-3 Trial Shows 83% Cut in HAE Attack Rate for Deucrictibant XR vs Placebo

Reuters
·
Sep 08

Pharvaris N.v. - Plans to Submit Nda to FDA for Deucrictibant Xr in First Half 2027

THOMSON REUTERS
·
Sep 08

Pharvaris N.v. - All Secondary Efficacy Endpoints Met with Statistical Significance in Chapter-3 Study

THOMSON REUTERS
·
Sep 08